2024年前三季，鱼跃医疗实现归母净利润15.32亿元，下滑了30.09%，显现业绩承压。 在市值变化方面，虽然鱼跃医疗的市值从14.73亿元稳步增长，目前已达到340.44亿元，增长幅度显著。但鱼跃医疗股价股价巅峰时 期在2015年4月17日，当日市值高达415.77亿元，报收41.90元。然而，最近4月17日交易数据集显示，总市值未340.44亿元，收盘价为 33.96元，市值较高位蒸发了18.12%。 鱼跃医疗（002223）自2008年4月18日上市以来，已走过17年的风雨历程。从初始市值仅为14.73亿元，到今天的340.44亿元，公司的 发展变化折射出中国医疗器械行业的飞速进步，然而鱼跃医疗的市值巅峰停留在2015年，至今10年仍未突破！作为一家专注于呼 吸、急救、康复等领域的医疗企业，鱼跃医疗不仅在国内市场占据了重要位置，也在全球范围内逐步开辟新的竞争空间。 鱼跃医疗的主营业务覆盖了医疗器械的多个重要领域，尤其在呼吸机、制氧机、自动体外除颤器(AED)等产品上具备明显优势。近年 来，公司更是在急救产品的研发和国际化扩展上不断加大投入。例如，其自主研发的AED产品已成功获得欧盟MDR认证，这不仅为 ...

据悉，本届德国iF设计奖由131位顶尖设计专家，从创新性、功能性、美学价值等九大维度对全球超 11000件作品展开评选。红点奖的评审团亦由30余国设计权威组成，获奖率不足5%的严苛筛选标准，使 每一件获奖作品都代表行业最高水准。 今年鱼跃医疗获奖产品呈现多方面亮点，在呼吸治疗、急救等多个领域都取得了优异的成绩。其中，斩 获双料大奖的HeartSave H7自动体外除颤器表现尤为抢眼，其独具新意的外观形态、便携形式和交互界 面设计都获得了高度评价，标志着该产品在多个设计领域的显著突破。 值得注意的是，HeartSave H7系列的创新之处不仅在于设计，其背后还蕴藏着一系列能与实际使用需求 深度结合的创新技术。例如，通过搭载内置摄像头，H7可实时传输急救画面至远程医疗平台，并结合 AI技术，精准捕捉按压频率、深度和位置等心肺复苏的操作细节，确保施救过程的规范性和有效性。 另一款在评选中脱颖而出的产品是Yuwell POCKET 呼吸机，它凭借出色的便携特性，以及追求极致的 设计品质，为有睡眠呼吸辅助需求的人群提供卓越的移动解决方案。通过与血氧指环搭配使用，可实时 监测血氧饱和度数据，为用户量身打造更为精准、安全的 ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)44鱼跃医疗19.6014.212.72340.44亿行业平均 44.7748.304.79102.17亿行业中值29.6628.912.3245.50亿1天益医疗-2726.44-2726.441.7120.28亿2硕世生 物-1821.98-1821.981.1537.64亿3诺唯赞-546.91-546.912.5198.96亿4博晖创新-359.25-221.193.9655.14亿5康 泰医学-261.9630.742.6850.95亿6华大基因-195.84214.222.02199.01亿7奥精医疗-109.30-109.301.3919.80亿 8睿昂基因-79.40-79.401.2311.48亿9热景生物-59.39-59.393.27106.45亿10华大智造-52.83-52.833.96316.51 亿11中红医疗-48.67-33.110.7743.33亿 来源：金融界 江苏鱼跃医疗设备股份有限公司的主营业务是研发、制造和销售医疗器械产品及提供相关解决方案。公 司产品主要集中在呼吸制氧、糖尿病护理、感染控制解决方案、家用类电子检 ...

Industry Overview - The Chinese medical device industry is expected to exceed 1.2 trillion yuan in market size in 2024, representing a year-on-year growth of approximately 2.2% [1] - The demand for home medical devices is increasing due to factors such as accelerated population aging and heightened health management awareness among various demographics [1] - The home medical device market reached 234.3 billion yuan in 2023, with a year-on-year growth of 12.32%, indicating significant market potential [1] Company Profile - Yuyue Medical, established in 1998, focuses on the home medical device sector, covering various categories such as blood pressure monitoring, temperature monitoring, and respiratory care [2] - The company has transitioned from hospital-grade equipment to home-use products, leveraging advancements in IoT, big data, and AI to enhance product offerings and user experience [2] Product Innovation - Yuyue Medical has launched numerous innovative products, including the third-generation sleep apnea machine, which features personalized treatment plans and smart temperature control [3] - The company emphasizes user experience by developing a smart health service system that includes IVR voice robots and a unified ticketing platform to better analyze user needs [3] Research and Development - Yuyue Medical has established multiple research and innovation platforms, including a national enterprise technology center and 12 R&D centers globally, to enhance its technological capabilities [4] - The company has accumulated 1,495 authorized patents as of the end of 2023, reflecting its commitment to innovation in the home medical device sector [4] - Yuyue Medical aims to participate in international competition and accelerate its global strategy through technological innovation [4]

江苏鱼跃医疗设备股份有限公司（以下简称"公司"）控股子公司江苏鱼跃 凯立特生物科技有限公司近日收到了国家药品监督管理局颁发的关于持续葡萄 糖监测系统（以下简称"CGM"）的《医疗器械注册证》。现将具体情况公告如 下： | 产品名称 | 持续葡萄糖监测系统 | | --- | --- | | 注册人名称 | 江苏鱼跃凯立特生物科技有限公司 | | 注册证编号 | 国械注准 20253070727 | | 注册分类 | III 类 | | 注册证有效期 | 2025 年 4 月 1 日至 2030 年 3 月 31 日 | | 型号、规格 | Anytime 5、Anytime 5Pro、Anytime 5P、Anytime 5H Pro、Anytime | | | 5H、Anytime 5h、Anytime 5h Pro、Anytime 5H SE | | 结构及组成 | 由传感器（探头）、发射器、助针器、软件（手机版发布版 3、 | | | 手表版发布版本 1）组成。 | | 适用范围 | 该产品可用于糖尿病成年患者（≥18 岁）的组织间液葡萄糖水 | | | 平的连续或定期监测，产品可提供并存储实时葡萄糖值 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Yuyue Medical, indicating a decline in revenue and net profit for the third quarter of 2024 compared to the previous year [1][2] - As of April 1, Yuyue Medical's stock closed at 35.68 yuan, with a PE ratio of 20.59 times, and a total market capitalization of 35.768 billion yuan [1] - The average PE ratio for the medical device industry is 46.46 times, with a median of 33.07 times, positioning Yuyue Medical at the 40th rank within the industry [1][2] Group 2 - For the third quarter of 2024, Yuyue Medical reported an operating income of 6.028 billion yuan, a year-on-year decrease of 9.53%, and a net profit of 1.532 billion yuan, down 30.09% year-on-year [2] - The company's sales gross margin stands at 50.13%, indicating a relatively stable profitability despite the decline in revenue and net profit [2] - Yuyue Medical specializes in the research, manufacturing, and sales of medical devices, focusing on areas such as respiratory oxygen, diabetes care, infection control solutions, and home electronic testing [1]

Core Viewpoint - Yuyue Medical has signed a strategic cooperation agreement with Inogen, a leading portable oxygen machine manufacturer in the U.S., marking a new phase in its North American market expansion and supporting its global strategy [1] Group 1: Company Overview - Founded in 1998, Yuyue Medical has become a leader in the domestic medical device industry, breaking the foreign brand monopoly through over 20 years of technological advancements [2] - The company offers a wide range of products across various fields, including respiratory oxygen, diabetes care, home testing, emergency care, traditional Chinese medicine, rehabilitation, disinfection, and ophthalmology, with over 600 product types and nearly 10,000 specifications [2] - Yuyue Medical serves 300,000 medical institutions globally, covering over 90% of top-tier hospitals in China and operating in 131 countries and regions [2] Group 2: Global Strategy and Market Expansion - In the first half of 2024, Yuyue Medical's overseas revenue reached 479 million yuan, a year-on-year increase of 30.19% [3] - The company has established over 50 channel agents in regions such as Southeast Asia, the Middle East, North Africa, and Europe and North America, creating a comprehensive R&D, production, marketing, and service network covering over 130 countries and regions [3] - Yuyue Medical has become a significant exhibitor at major international medical device exhibitions, enhancing the global perception of Chinese medical device brands [3] Group 3: Product Quality and Certifications - Yuyue Medical has accelerated the acquisition of overseas market access qualifications, obtaining 64 overseas registrations in 2023 and 52 in the first half of 2024 [4] - Key products have received certifications from the U.S. FDA, EU MDR, and Korea KGMP, establishing a solid foundation for market expansion [4] - The company's automated external defibrillator (AED) recently passed the EU's Class III medical device CE certification, facilitating rapid growth in its emergency business in the EU and other countries recognizing EU MDR certification [4] Group 4: Innovation and Future Outlook - Yuyue Medical emphasizes strict quality control and continuous innovation as the foundation of its successful global strategy [4] - The company is advancing digital transformation by introducing leading smart production lines and establishing national-level smart manufacturing factories to ensure product quality through comprehensive data management [4] - Yuyue Medical plans to continue focusing on user needs, increasing R&D investment, and enhancing product quality and service capabilities to achieve greater breakthroughs in the global market [5]

Core Viewpoint - The article highlights the issues surrounding the accuracy of Yuwell's blood pressure monitors, which have led to consumer dissatisfaction and declining financial performance for Yuwell Medical, the parent company. Financial Performance - Yuwell Medical reported a revenue of 6.028 billion yuan for the first nine months of 2024, a year-on-year decline of 9.53% [10] - The net profit for the same period was 1.532 billion yuan, down 30.09% year-on-year, while the net profit after deducting non-recurring items was 1.274 billion yuan, a decrease of 23.74% [10] - The company’s market capitalization as of March 31, 2025, was 34.966 billion yuan, significantly below its target of 100 billion yuan in revenue and 1 trillion yuan in market value by 2025 [11] Consumer Feedback - A survey on Weibo indicated that 50.4% of respondents believed Yuwell's blood pressure monitors were "not very accurate" or "completely inaccurate," while only 5.5% found them "very accurate" [1] - Consumers reported significant discrepancies in blood pressure readings, with some experiencing measurement errors as high as 20-30 mmHg [4][5] Company Background - Yuwell Medical was founded in 1998 and has grown through a series of acquisitions, expanding its product range to include over 600 types of medical devices [6][7] - The company has faced increasing scrutiny over product quality, with numerous complaints and regulatory penalties in recent years [8] Strategic Challenges - The company is experiencing a decline in revenue and profit, attributed to a saturated market and increased competition in the medical device sector [2][10] - Yuwell Medical's R&D expenditure as a percentage of revenue is relatively low at 6.26%, ranking 48th among 59 listed healthcare equipment companies, indicating a potential weakness in innovation [10] Future Outlook - Yuwell Medical aims to focus on core business areas such as respiratory therapy, diabetes care, and home testing, while emphasizing innovation and R&D to drive future growth [10]

Core Insights - Yuyue Medical's stock closed at 35.48 yuan, down 1.11%, with a rolling PE ratio of 20.48 times and a total market capitalization of 35.568 billion yuan [1] - The average PE ratio for the medical device industry is 45.22 times, with a median of 32.57 times, placing Yuyue Medical at the 42nd position in the industry ranking [1] - As of February 28, 2025, Yuyue Medical had 40,000 shareholders, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Company Overview - Jiangsu Yuyue Medical Equipment Co., Ltd. specializes in the research, manufacturing, and sales of medical devices, along with providing related solutions [1] - The company's product range includes respiratory oxygen, diabetes care, infection control solutions, home electronic testing, in vitro diagnostics, emergency and clinical rehabilitation devices [1] - Yuyue Medical owns several major brands, including "Yuyue," "Jiefuro," "Huatuo," "Jinzhong," "An'er iodine," "Primedic," and "Liuliu Vision," with significant brand value and advantages due to effective brand communication and product performance [1] Financial Performance - In the latest quarterly report for Q3 2024, the company reported revenue of 6.028 billion yuan, a year-on-year decrease of 9.53%, and a net profit of 1.532 billion yuan, down 30.09% [2] - The sales gross margin for the company stands at 50.13% [2] - The PE ratio (TTM) for Yuyue Medical is 20.48, while the industry average is 45.22, indicating a significant valuation gap [2]

证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-009 江苏鱼跃医疗设备股份有限公司 关于与专业投资机构共同投资的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本次投资的概述 江苏鱼跃医疗设备股份有限公司（以下简称"本公司"、"公司"）与上海 盛宇股权投资基金管理有限公司（以下简称"盛宇投资"）、丹阳盛宇高鑫股权 投资合伙企业（有限合伙）、上海锍晟投资中心（有限合伙）（以下简称"锍晟 投资"）、江苏中盈投资管理有限公司、上海松江创业投资管理有限公司等参与 方共同投资设立南京盛宇黑科新智造创业投资合伙企业（有限合伙）（以下简称 "合伙企业"或"基金"），基金的普通合伙人及基金管理人为盛宇投资。基金 认缴规模为人民币 30,000 万元，其中，本公司以自有资金出资认缴不超过人民 币 10,000 万元。合伙企业已经完成工商备案登记，收到了南京市雨花台区行政 审批局颁发的营业执照，并已在中国证券投资基金业协会完成备案手续，取得《私 募投资基金备案证明》。 2025 年 1 月 11 日，公司披露了《关于与专业投资机构共同投资的进展公 告》 ...